Investment

Features

Pro Tools for Pro Traders

Uncover the powerful trading features

Pro Features

Pluang Web Trading

Leverage

Built for Investors

Experience investing with simplified features

Pockets

Recurring Buy

USD Yield

Pluang Cuan

Fees

Safety

Academy

Latest for You

Get up-to-date financial news and investing tips & information

Blog

Find various tips & information to become a knowledgeable investor

News and Analysis

Read the latest information about finance and investment

Learn

Become a smarter investor by learning the basics of investing

Glossary

Learn investment terms to understand investing better

Promo & Referral

Discover exclusive opportunities to level up your investments

Investment Clubs (Coming Soon)

Join hands with like-minded investors to grow wealth together

Press (Coming Soon)

Stay updated with our latest news and media coverage

Support

About Us

Contact

Ask

Career

Tax Reporting Guide

Pluang+

Regeneron Pharmaceuticals Inc (REGN) Stock Price Today

Overview

Financial

Technicals

Analysis

Corporate Action

About

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Technical Indicators

Overall Summary

Bearish (3)

Neutral (9)

Bullish (15)

Performance

REGN ROI

+40.93%

% from 52W High

-3.31%

$1,162

52W Low: $775.18

27 Oct 2023

52W High: $1,201.76

27 Aug 2024

News

Globe Newswire

Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)

Globe Newswire

10d

Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer

Benzinga

10d

GSK's Respiratory Drug Nucala Meets Goal in COPD Study

The Motley Fool

14d

Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030

Globe Newswire

Retinoblastoma Treatment Market to Surpass $2 Billion in 2024, Exhibiting a CAGR of 5.5% - Global Long-term Forecasts to 2028 and 2033

US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions